Search results for "neuroendocrine tumor"

showing 10 items of 71 documents

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unk…

2021

Abstract Background Poorly differentiated neuroendocrine carcinomas (NEC) are rare diseases with a poor prognosis. Platinum-etoposide (PE) has been the recommended first-line treatment for decades. FOLFIRINEC (NCT04325425) is a national multicenter randomized phase II study which aims to challenge this standard regimen. Methods The primary objective is to compare the median progression-free survival (PFS) under mFOLFIRINOX versus PE. The secondary objectives are to evaluate the objective response rates (ORR), median overall survival (OS), safety and quality of life. The associated real-time translational study will establish a molecular profile for each patient enrolled. Main inclusion crit…

OncologyMaleFOLFIRINOXmedicine.medical_treatmentLeucovorinPhases of clinical researchPlatinum Compounds0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesNeoplasm MetastasisEtoposideEtoposideGastroenterologyEvaluable DiseaseProgression-Free Survival3. Good healthFOLFIRINOXOxaliplatinSurvival RateNeuroendocrine TumorsTreatment Outcome030220 oncology & carcinogenesisNeuroendocrine carcinoma030211 gastroenterology & hepatologyFemaleFluorouracilmedicine.drugAdultmedicine.medical_specialtyIrinotecanGastroenteropancreatic03 medical and health sciencesStomach NeoplasmsInternal medicineIntestinal NeoplasmsmedicineChemotherapyHumansContraindicationChemotherapyHepatologyPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyCarcinoma NeuroendocrinePancreatic NeoplasmsRegimenQuality of LifeNeoplasms Unknown PrimarybusinessBiomarkersDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

The Vegf Pathway in Patients with Pancreatic Neuroendocrine Tumors: Efficacy of Everolimus by Baseline Marker Level, and Prognostic and Predictive Ef…

2012

ABSTRACT Background RADIANT-3 was a phase III study investigating the effect of the mammalian target of rapamycin inhibitor everolimus on progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumors (pNET; Yao et al, NEJM, 2011). Everolimus significantly improved PFS compared with placebo (11 vs 4.6 months, P  Methods Baseline plasma levels of VEGF-A, PlGF, sVEGFR1, and sVEGFR2 were determined by ELISA using multiplexed MSD platform. The optimal cutoffs for these markers were explored using the “survival tree analysis” method. Interaction of treatment and baseline marker status ( Results PFS was significantly improved to a similar extent in patients receiving e…

Oncologymedicine.medical_specialtyEverolimusbusiness.industryHematologyPlasma levelsNeuroendocrine tumorsmedicine.diseasePlaceboOncologyMarker statusInternal medicinemedicineIn patientTreatment effectbusinessSurvival treemedicine.drugAnnals of Oncology
researchProduct

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and L…

2020

Background: Lung neuroendocrine carcinoma (NEC) is characterized by aggressive clinical behavior and lack of treatment advances. We evaluate the prognostic and the predictive roles of systemic inflammatory biomarkers in patient circulating blood: neutrophil–lymphocyte ratio (NLR), lactate dehydrogenase (LDH), advanced lung cancer inflammation index (ALI), and the Lung Immune Prognostic Index (LIPI) score. Methods: A total of 120 patients with small-cell lung cancer (SCLC) ( n = 110) and large cell neuroendocrine carcinoma (LCNEC) ( n = 10) were enrolled. Overall survival (OS) was evaluated by Kaplan–Meier estimator and univariate and multivariate Cox proportional hazard analyses were perfor…

Oncologymedicine.medical_specialtyLungBlood based biomarkersbusiness.industrySettore MED/06 - Oncologia Medicasmall-cell lung cancer (SCLC)systemic inflammatory responselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensInflammatory biomarkerslcsh:RC254-282Neuroendocrine Carcinomasmedicine.anatomical_structureOncologyInternal medicinemedicinePrognostic biomarkerNeuroendocrine carcinomaOriginal Articlebusinesspredictive biomarkerprognostic biomarkerneuroendocrine tumorPredictive biomarkerblood-based biomarker
researchProduct

The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

2018

Purpose: Analyze the role of somatostatin analogues (SSAs) in the treatment of sporadic and MEN1-related gastrinomas, trying to define whether recent trials have changed the landscape of gastrinoma therapy. Methods: We evaluate the rationale of SSA use in the treatment of gastrinomas, summarize the current literature concerning the effect of SSAs on the control of Zollinger-Ellison syndrome (ZES) and gastrinomas tumor progression and discuss their role in the most recent guidelines. Results: The medical treatment of gastrinoma and related ZES is aimed at controlling acid hypersecretion and tumor progression, in inoperable patients. The use of proton pump inhibitors (PPIs) to control the syn…

Oncologymedicine.medical_specialtyProton Pump InhibitorAntineoplastic Agents HormonalEndocrinology Diabetes and MetabolismGastrinoma; neuroendocrine tumours; somatostatin; somatostatin analogues; endocrinology; diabetes and metabolism; endocrinologyNeuroendocrine tumorssomatostatinOctreotideSomatostatin analogueSettore MED/13 - EndocrinologiaZollinger-Ellison Syndrome03 medical and health sciencesendocrinology0302 clinical medicineInternal medicineNeuroendocrine tumourmedicineHumansProgression-free survivaldiabetes and metabolismGastrinomaMedical treatmentsomatostatin analoguesbusiness.industryDisease progressionPancreatic NeoplasmProton Pump Inhibitorsmedicine.diseasedigestive system diseasesZollinger-Ellison syndromePancreatic NeoplasmsEndocrinologySomatostatinTreatment OutcomeTumor progression030220 oncology & carcinogenesisGastrinoma030211 gastroenterology & hepatologyneuroendocrine tumoursbusinessHuman
researchProduct

Vulvar cancer: a review for dermatologists.

2015

Vulvar malignancies are important tumors of the female reproductive system. They represent a serious health issue with an incidence between 2 and 7 per 100,000 and year. We provide a review about most important cancer entities, i.e., melanoma, squamous cell carcinoma, basal cell carcinoma, neuroendocrine cancer, and skin adnexal malignancies. Squamous cell carcinoma is the most common vulvar malignancy that can develop from vulvar intraepithelial neoplasia or de novo. Basal cell carcinoma represents only 2 % of all vulvar cancers. Melanoma of the vulva exists in two major types—superficial spreading and acral lentiginous. A special feature is the occurrence of multiple vulvar melanomas. Of …

Oncologymedicine.medical_specialtySkin NeoplasmsMalignancyVulvaVulvaDiagnosis DifferentialVulva · Squamous cell carcinoma · Basal cell carcinoma · Melanoma · Paget’s disease · Adnexal carcinomasInternal medicineCarcinomamedicineSettore MED/35 - Malattie Cutanee E VenereeHumansBasal cell carcinomaMelanomaNeoplasm StagingSkinintegumentary systemVulvar Neoplasmsurogenital systembusiness.industryMelanomaCancerGeneral MedicineVulvar cancermedicine.diseaseVulvar intraepithelial neoplasiaPrognosisDermatologyfemale genital diseases and pregnancy complicationsNeuroendocrine Tumorsmedicine.anatomical_structurePaget Disease ExtramammaryCarcinoma Basal CellCarcinoma Squamous CellFemaleNeoplasms Adnexal and Skin AppendagebusinessCarcinoma in SituWiener medizinische Wochenschrift (1946)
researchProduct

Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal.

2020

Neuroendocrine tumors (NETs) frequently overexpress somatostatin receptors (SSTR) on their cell surface. The first-line pharmacological treatment for inoperable metastatic functioning well-differentiated NETs are somatostatin analogs. On second line, Lu-DOTA-TATE (177Lu-DOTA0 Tyr 3 octreotate) has shown stabilization of the disease and an increase in progression free survival, as well as effectiveness in controlling symptoms and increasing quality of life. The management of functional NETs before and during LU-DOTA-TATE treatment is specially challenging, as several complications such as severe carcinoid and catecholamine crisis have been described. The aim of this review is to establish pr…

Oncologymedicine.medical_specialtycatecholaminergic crisisMEDLINElcsh:Medicinecarcinoid syndrome030209 endocrinology & metabolismReviewNeuroendocrine tumors03 medical and health scienceschemistry.chemical_compound0302 clinical medicinesystematic reviewInternal medicinemedicinecarcinoid crisisProgression-free survivalDOTA-TATEpeptide receptor radionuclide therapyhormonal crisisOctreotatebusiness.industrySomatostatin receptorlcsh:RGeneral Medicinemedicine.diseaseSystematic reviewchemistry030220 oncology & carcinogenesisneuroendocrine tumorsbusiness177Lu-DOTA-TATECarcinoid syndromeJournal of clinical medicine
researchProduct

Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours.

2013

Little is known about patients with malignant digestive neuroendocrine tumours (MD-NETs). Although their incidence is increasing, MD-NETs remain a rare cancer, representing 1% of digestive cancers. Most MD-NETs are well-differentiated. MD-NET poorly differentiated carcinomas account for 20% of cases on average. Anatomical localisation of MD-NETs varied according to geographic region. Stage at diagnosis and prognosis for patients with MD-NETs in the general population are considerably worse than often reported from small hospital case series. Prognosis varies with tumour differentiation, anatomic site and histological subtype. There are significant differences in survival from MD-NETs among …

Oncologymedicine.medical_specialtyeducation.field_of_studybusiness.industryEndocrinology Diabetes and MetabolismPoorly differentiatedIncidence (epidemiology)PopulationGeneral MedicineRare cancerSmall hospitalNeuroendocrine TumorsEndocrinologyEndocrinologyInternal medicineEpidemiologyEndocrine Gland NeoplasmsmedicineEndocrine systemAnimalsHumansbusinesseducationDigestive cancerGastrointestinal NeoplasmsEuropean journal of endocrinology
researchProduct

Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and indivi…

2022

Background and aims: Therapy and prognosis of pancreatic neuroendocrine tumors (PanNETs) are strictly related to the Ki-67 index, which defines tumor grading. The criterion standard for the assessment of grading of PanNETs is EUS-guided FNA (EUS-FBAFNA) or EUS-guided fine-needle biopsy sampling (EUS-FNB). Because data on diagnostic accuracy of EUS-FNA and EUS-FNB are heterogeneous, we aimed to analyze the variability in concordance between EUS grading and surgical grading. Methods: The MEDLINE, SCOPUS, and EMBASE databases were searched until November 2021 to identify studies reporting the concordance rate between EUS grading and surgical grading. The study was conducted in accordance with …

Pancreatic NeoplasmspancreaNeuroendocrine TumorsKi-67 Antigenendoscopic ultrasoundGastroenterologyKi-67HumansReproducibility of ResultsRadiology Nuclear Medicine and imagingEndoscopic Ultrasound-Guided Fine Needle Aspirationneuroendocrine tumorGastrointestinal Endoscopy
researchProduct

Evaluation of polysialic acid in the diagnosis of Wilms' tumor. A comparative study on urinary tract tumors and non-neuroendocrine tumors.

1988

The polysialic acid moiety of the neural cell adhesion molecule has been shown to represent an onco-developmental antigen which can be detected in both embryonic human kidney and Wilms’ tumor but not in normal adult human kidney. In the present comparative study, Wilms’ tumors, clear cell (bone-metastasizing) sarcomas of kidney, cystic nephromas, renal cell carcinomas, transitional cell carcinomas and papillomas of the renal pelvis, ureter and urinary bladder (as well normal transitional epithelium from these regions), Ewing sarcomas, hepatoblastomas, rhabdomyosarcomas, and carcinomas of the stomach, colon, exocrine pancreas, lung, and esophagus, were investigated immunohistochemically for …

Pathologymedicine.medical_specialtyKidneyUrologic NeoplasmsPolysialic acidImmunoblottingAntibodies MonoclonalWilms' tumorGeneral MedicineBiologyNeuroendocrine tumorsTransitional epitheliummedicine.diseaseImmunohistochemistryWilms TumorKidney NeoplasmsMicemedicine.anatomical_structuremedicineBiomarkers TumorSialic AcidsAnimalsNeural cell adhesion moleculeRenal pelvisClear cellVirchows Archiv. B, Cell pathology including molecular pathology
researchProduct

Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours

2021

Abstract Aim Gallium-68-labelled inhibitors of the fibroblast activation protein (FAPi) enable positron emission tomography/computed tomography (PET/CT) imaging of fibroblast activation. We evaluated if [68Ga]Ga-DATA5m.SA.FAPi PET/CT is related to Ki-67 as a marker of tumour aggressiveness in patients with liver metastases of NET. Methods Thirteen patients with liver metastases of a histologically confirmed NET who underwent PET/CT with [68Ga]Ga-DATA5m.SA.FAPi, [18F]FDG and [68Ga]Ga-DOTA-TOC were retrospectively analyzed. PET-positive liver tumour volumes were segmented for calculation of volume, SUVmax and PET-positive tumour fraction (TF). PET parameters were correlated with Ki-67. Result…

Pathologymedicine.medical_specialtyProliferation index030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineFibroblast activation protein alphaPositron Emission Tomography Computed TomographymedicineHumansRadiology Nuclear Medicine and imagingIn patientFibroblastGrading (tumors)Retrospective StudiesPET-CTbiologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsGeneral MedicineFibroblastsNeuroendocrine TumorsKi-67 Antigenmedicine.anatomical_structurePositron emission tomography030220 oncology & carcinogenesisKi-67biology.proteinbusinessNuklearmedizin - NuclearMedicine
researchProduct